In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin
- PMID: 12183253
- PMCID: PMC127454
- DOI: 10.1128/AAC.46.9.2956-2962.2002
In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin
Abstract
Abilities of amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin to select resistant mutants of Haemophilus influenzae were tested by multistep and single-step methodologies. For multistep studies, 10 random strains were tested: 5 of these were beta-lactamase positive. After 50 daily subcultures in amoxicillin-clavulanate, MICs did not increase more than fourfold. However, cefprozil MICs increased eightfold for one strain. Clarithromycin and azithromycin gave a >4-fold increase in 8 and 10 strains after 14 to 46 and 20 to 50 days, respectively. Mutants selected by clarithromycin and azithromycin were associated with mutations in 23S rRNA and ribosomal proteins L4 and L22. Three mutants selected by clarithromycin or azithromycin had alterations in ribosomal protein L4, while five had alterations in ribosomal protein L22. Two mutants selected by azithromycin had mutations in the gene encoding 23S rRNA: one at position 2058 and the other at position 2059 (Escherichia coli numbering), with replacement of A by G. One clone selected by clarithromycin became hypersusceptible to macrolides. In single-step studies azithromycin and clarithromycin had the highest mutation rates, while amoxicillin-clavulanate had the lowest. All resistant clones were identical to parents as observed by pulsed-field gel electrophoresis. The MICs of azithromycin for azithromycin-resistant clones were 16 to >128 micro g/ml, and those of clarithromycin for clarithromycin-resistant clones were 32 to >128 micro g/ml in multistep studies. For strains selected by azithromycin, the MICs of clarithromycin were high and vice versa. After 50 daily subcultures in the presence of drugs, MICs of amoxicillin-clavulanate and cefpodoxime against H. influenzae did not rise more than fourfold, in contrast to cefprozil, azithromycin, and clarithromycin, whose MICs rose to variable degrees.
Figures


Similar articles
-
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.Antimicrob Agents Chemother. 2004 Nov;48(11):4113-9. doi: 10.1128/AAC.48.11.4113-4119.2004. Antimicrob Agents Chemother. 2004. PMID: 15504829 Free PMC article.
-
Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.Antimicrob Agents Chemother. 1998 Dec;42(12):3193-9. doi: 10.1128/AAC.42.12.3193. Antimicrob Agents Chemother. 1998. PMID: 9835514 Free PMC article.
-
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.Antimicrob Agents Chemother. 2006 Jun;50(6):2050-7. doi: 10.1128/AAC.00044-06. Antimicrob Agents Chemother. 2006. PMID: 16723565 Free PMC article.
-
Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.Diagn Microbiol Infect Dis. 2007 Mar;57(3 Suppl):5S-12S. doi: 10.1016/j.diagmicrobio.2006.12.014. Epub 2007 Feb 9. Diagn Microbiol Infect Dis. 2007. PMID: 17292577 Review.
-
Clinical experience with cefpodoxime proxetil in acute otitis media.Pediatr Infect Dis J. 1995 Apr;14(4 Suppl):S12-8. doi: 10.1097/00006454-199504001-00003. Pediatr Infect Dis J. 1995. PMID: 7792125 Review.
Cited by
-
Exit tunnel modulation as resistance mechanism of S. aureus erythromycin resistant mutant.Sci Rep. 2019 Aug 7;9(1):11460. doi: 10.1038/s41598-019-48019-1. Sci Rep. 2019. PMID: 31391518 Free PMC article.
-
Mechanism of action, resistance, synergism, and clinical implications of azithromycin.J Clin Lab Anal. 2022 Jun;36(6):e24427. doi: 10.1002/jcla.24427. Epub 2022 Apr 21. J Clin Lab Anal. 2022. PMID: 35447019 Free PMC article. Review.
-
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.Antimicrob Agents Chemother. 2004 Nov;48(11):4113-9. doi: 10.1128/AAC.48.11.4113-4119.2004. Antimicrob Agents Chemother. 2004. PMID: 15504829 Free PMC article.
-
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model.Antimicrob Agents Chemother. 2020 May 21;64(6):e02265-19. doi: 10.1128/AAC.02265-19. Print 2020 May 21. Antimicrob Agents Chemother. 2020. PMID: 32284378 Free PMC article.
-
Phylogenetic and functional characterisation of the Haemophilus influenzae multidrug efflux pump AcrB.Commun Biol. 2019 Sep 13;2:340. doi: 10.1038/s42003-019-0564-6. eCollection 2019. Commun Biol. 2019. PMID: 31531401 Free PMC article.
References
-
- Baquero, F. 1999. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J. Chemother. 11:35-43. - PubMed
-
- Baquero, F. 1996. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J. Antimicrob. Chemother. 38(Suppl. A):117-132. - PubMed
-
- Barcak, G. J., M. S. Chandler, R. J. Redfield, and J. F. Tomb. 1991. Genetic systems in Haemophilus influenzae. Methods Enzymol. 204:321-342. - PubMed
-
- Craig, W. A. 2001. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. Respir. Med. 95(Suppl. A):S12-9, S26-S27. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases